{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:09:02Z","timestamp":1792271342906,"version":"4.4.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clml.2022.01.011","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T18:54:13Z","timestamp":1642618453000},"page":"460-473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.01.011_bib0001","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.01.011_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.clml.2022.01.011_bib0003","unstructured":"National Cancer Institute. Cancer stat facts: myeloma. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed July 2, 2020."},{"key":"10.1016\/j.clml.2022.01.011_bib0004","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0145-2126(12)70003-6","article-title":"Can we change the disease biology of multiple myeloma?","volume":"36","author":"Borrello","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.01.011_bib0005","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bmt.2015.307","article-title":"Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity","volume":"51","author":"Cornell","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2022.01.011_bib0006","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1038\/leu.2014.140","article-title":"Gene expression profile alone is inadequate in predicting complete response in multiple myeloma","volume":"28","author":"Amin","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.011_bib0007","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.011_bib0008","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.011_bib0009","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines clinical practice guidelines in oncology: Version 2.2021 Multiple Myeloma. Version 2.2021. Available at: https:\/\/nccn.org\/. Accessed June 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0010","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.011_bib0011","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/asheducation-2017.1.508","article-title":"Management of multiple myeloma in the relapsed\/refractory patient","volume":"2017","author":"Sonneveld","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2022.01.011_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-018-3546-8","article-title":"Navigating the treatment landscape in multiple myeloma: which combinations to use and when?","volume":"98","author":"Goldschmidt","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.01.011_bib0013","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.011_bib0014","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1179\/1607845414Y.0000000218","article-title":"Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: a retrospective study","volume":"20","author":"Oriol","year":"2015","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2022.01.011_bib0015","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.bbmt.2015.03.026","article-title":"Autologous stem cell transplantation is an effective salvage therapy for primary refractory multiple myeloma","volume":"21","author":"Parrish","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2022.01.011_bib0016","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1445-5994.2012.02867.x","article-title":"Relapsed multiple myeloma: who benefits from salvage autografts?","volume":"43","author":"Chow","year":"2013","journal-title":"Intern Med J"},{"key":"10.1016\/j.clml.2022.01.011_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment options for triple-class refractory multiple myeloma","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.01.011_bib0018","unstructured":"Celgene. Pomalyst\u24c7 (pomalidomide) Prescribing Information. Available at: http:\/\/www.celgene.com\/content\/uploads\/pomalyst-pi.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0019","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.01.011_bib0020","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.011_bib0021","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","article-title":"Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets","volume":"125","author":"Sehgal","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0022","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2014.238","article-title":"In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone","volume":"29","author":"Ocio","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.011_bib0023","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/bjh.13905","article-title":"Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma","volume":"172","author":"Rychak","year":"2016","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.clml.2022.01.011_bib0024","unstructured":"Celgene. Imnovid\u24c7 (pomalidomide) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imnovid-epar-product-information_en.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0025","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone vs. high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San-Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.011_bib0026","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0027","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0028","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.011_bib0029","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0030","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2018-99-114029","article-title":"Carfilzomib, pomalidomide and dexamethasone (KPd) in patients with multiple myeloma refractory to bortezomib and lenalidomide. The EMN011 trial","volume":"132","author":"Sonneveld","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0031","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41375-018-0038-8","article-title":"Phase I\/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"32","author":"Krishnan","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.011_bib0032","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.1016\/j.clml.2022.01.011_bib0033","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/01.HS9.0000563756.72895.a3","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: Efficacy results after additional follow-up of the phase 2, randomized ELOQUENT-3 study","volume":"2","author":"Dimopoulos","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2022.01.011_bib0034","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0035","doi-asserted-by":"crossref","unstructured":"Dimopoulos M.A., Terpos E., Boccadaro M., Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Vs. Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM). Oral presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition; December 5\u20138, 2020; Abstract 653.","DOI":"10.1182\/blood-2020-135874"},{"key":"10.1016\/j.clml.2022.01.011_bib0036","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/s41375-020-0813-1","article-title":"Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment","volume":"34","author":"Siegel","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.011_bib0037","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134189","article-title":"Pomalidomide, dexamethasone, and daratumumab after lenalidomide treatment in relapsed refractory multiple myeloma: updated results from an open-label, multicenter, phase 2 trial","volume":"136","author":"Siegel","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0038","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone vs. pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.01.011_bib0039","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone vs. bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.011_bib0040","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.clml.2019.04.018","article-title":"Carfilzomib-dexamethasone vs. bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups","volume":"19","author":"Orlowski","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.01.011_bib0041","unstructured":"Amgen. Kyprolis\u24c7 (carfilzomib) Prescribing Information. Available at: https:\/\/www.pi.amgen.com\/\u223c\/media\/amgen\/repositorysites\/pi-amgen-com\/kyprolis\/kyprolis_pi.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0042","unstructured":"Amgen. Kyprolis\u24c7 (carfilzomib) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kyprolis-epar-product-information_en.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0043","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.011_bib0044","first-page":"102","article-title":"Ninlaro (Ixazomib): first oral proteasome inhibitor approved for the treatment of patients with relapsed or refractory multiple myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.clml.2022.01.011_bib0045","unstructured":"Takeda Pharmaceutical Company Limited. Ninlaro\u24c7 (ixazomib) Prescribing Information. Available at: https:\/\/www.ninlaro.com\/prescribing-information.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0046","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.011_bib0047","unstructured":"Takeda Pharma A\/S. Ninlaro\u24c7 (ixazomib) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ninlaro-epar-product-information_en.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0048","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-019-0219-3","article-title":"Phase I\/II trial of bendamustine, ixazomib, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"9","author":"Dhakal","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.01.011_bib0049","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2022.01.011_bib0050","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0051","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clml.2022.01.011_bib0052","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-17-0998","article-title":"Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab","volume":"17","author":"Kurdi","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2022.01.011_bib0053","unstructured":"Bristol Myers Squibb. Empliciti\u24c7 (elotuzumab) Prescribing Information. Available at: http:\/\/packageinserts.bms.com\/pi\/pi_empliciti.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0054","unstructured":"Bristol Myers Squibb. Empliciti\u24c7 (elotuzumab) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/empliciti-epar-product-information_en.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0055","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2022.01.011_bib0056","unstructured":"Janssen. Darzalex\u24c7 (daratumumab) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/darzalex-epar-product-information_en.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0057","unstructured":"Janssen. Darzalex\u24c7 (daratumumab) Prescribing Information. Available at: http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/DARZALEX-pi.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0058","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.01.011_bib0059","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00432-020-03365-w","article-title":"Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results","volume":"147","author":"Usmani","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.011_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous vs. intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.01.011_bib0061","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0062","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-132629","article-title":"Carfilzomib, dexamethasone, and daratumumab vs. carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM): Primary analysis results from the randomized, open-label, phase 3 study Candor (NCT03158688)","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0063","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab vs. carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.01.011_bib0064","doi-asserted-by":"crossref","unstructured":"Dimopoulos M.A., Quach H., Mateos M.-V., Carfilzomib, Dexamethasone, and Daratumumab Vs. Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study. Poster presentation at: the American Society of Hematology (ASH) Annual Meeting & Exposition. December 5\u20138, 2020. Poster 2325.","DOI":"10.1182\/blood-2020-137602"},{"key":"10.1016\/j.clml.2022.01.011_bib0065","unstructured":"Sanofi Genzyme. Sarclisa\u24c7 (isatuximab) Prescribing Information. Available at: https:\/\/products.sanofi.us\/Sarclisa\/Sarclisa.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0066","unstructured":"Sanofi-Aventis Groupe. Sarclisa\u24c7 (isatuximab) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sarclisa-epar-product-information_en.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0067","unstructured":"Moreau P., Dimopoulos M., Mikhael J., Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma (IKEMA): Interim analysis of a phase 3, randomized, open-label study. Oral presentation at: the European Hematology Association (EHA) Annual Meeting; June 11\u201314, 2020. Abstract LB2603."},{"key":"10.1016\/j.clml.2022.01.011_bib0068","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.011_bib0069","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/1060028019892643","article-title":"Selinexor: a first-in-class nuclear export inhibitor for management of multiply relapsed multiple myeloma","volume":"54","author":"Peterson","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clml.2022.01.011_bib0070","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.011_bib0071","unstructured":"Karyopharm. Xpovio\u24c7 (selinexor) Prescribing Information. Available at: https:\/\/www.karyopharm.com\/wp-content\/uploads\/2019\/07\/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0072","unstructured":"Karyopharm Europe GmbH. Nexpovio\u24c7 (selinexor) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/documents\/product-information\/nexpovio-epar-product-information_en.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0073","unstructured":"Chen C.I., Bahlis N.J., Gasparetto C., Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM). Oral presentation at: the American Society of Hematology (ASH) Annual Meeting & Exposition. December 5\u20138, 2020. Abstract 726."},{"key":"10.1016\/j.clml.2022.01.011_bib0074","doi-asserted-by":"crossref","unstructured":"Dimopoulos M., Delimpasi S., Simonova M., Weekly selinexor, bortezomib, and dexamethasone (SVd) vs. twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study. Oral presentation at: the American Society of Clinical Oncology Annual Meeting; May 29\u201331, 2020. Abstract 8501.","DOI":"10.1200\/JCO.2020.38.15_suppl.8501"},{"key":"10.1016\/j.clml.2022.01.011_bib0075","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjh.15969","article-title":"Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed\/refractory multiple myeloma","volume":"186","author":"Jakubowiak","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.011_bib0076","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.clml.2019.12.013","article-title":"Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"20","author":"Salcedo","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.01.011_bib0077","unstructured":"Secura Bio. Farydak\u24c7 (panobinostat) Prescribing Information. Available at: https:\/\/us.farydak.com\/assets\/pdf\/Farydak-SBI-USPI-201909.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0078","unstructured":"Secura Bio Limited. Farydak\u24c7 (panobinostat) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/documents\/product-information\/farydak-epar-product-information_en.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0079","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","article-title":"PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0080","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1470-2045(20)30680-X","article-title":"Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study","volume":"22","author":"Laubach","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.011_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(16)30165-X","article-title":"Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1\/2 trial","volume":"3","author":"Popat","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.01.011_bib0082","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.15551","article-title":"Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I\/II Clinical Trial)","volume":"185","author":"Popat","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.011_bib0083","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3324\/haematol.2014.119735","article-title":"Phase I\/II study of the combination of panobinostat and carfilzomib in patients with relapsed\/refractory multiple myeloma","volume":"100","author":"Berdeja","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.01.011_bib0084","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-136307","article-title":"CARTITUDE-1: Phase 1b\/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0085","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.011_bib0086","unstructured":"Bristol Myers Squibb. ABECMA\u24c7 (idecabtagene vicleucel) Prescribing Information. Available at: https:\/\/packageinserts.bms.com\/pi\/pi_abecma.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0087","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orvacel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.011_bib0088","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0089","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1200\/JCO.2020.38.15_suppl.8505","article-title":"Update of CARTITUDE-1: A phase Ib\/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed\/refractory multiple myeloma","volume":"38","author":"Berdeja","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.011_bib0090","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2019-126660","article-title":"Updated results from an ongoing phase 1 clinical study of bb21217 anti-BCMA CAR T cell therapy","volume":"134","author":"Berdeja","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0091","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-134383","article-title":"Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma","volume":"136","author":"Kansagra","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0092","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-136360","article-title":"Cytokine Release Syndrome in Patients with Relapsed\/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b\/2 CARTITUDE-1 Study","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0093","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-019-1092-1","article-title":"Recent updates on CAR T clinical trials for multiple myeloma","volume":"18","author":"Lin","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clml.2022.01.011_bib0094","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.011_bib0095","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3389\/fimmu.2020.01155","article-title":"Targeted Therapy With Immunoconjugates for Multiple Myeloma","volume":"11","author":"Bruins","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2022.01.011_bib0096","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-Cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.011_bib0097","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0098","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-138831","article-title":"Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and\/or Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Garfall","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0099","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3390\/cancers12061473","article-title":"BCMA-targeting therapy: driving a new era of immunotherapy in multiple myeloma","volume":"12","author":"Cho","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2022.01.011_bib0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-137743","article-title":"First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"van de Donk","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0101","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2020.38.15_suppl.8500","article-title":"First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Richardson","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.011_bib0102","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.011_bib0103","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2019-126015","article-title":"Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"134","author":"Moreau","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0104","unstructured":"GlaxoSmithKline. Blenrep\u24c7 (belantamab mafodotin) Prescribing Information. Available at: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Blenrep\/pdf\/BLENREP-PI-MG.PDF. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0105","unstructured":"GlaxoSmithKline (Ireland) Limited. Blenrep\u24c7 (belantamab mafodotin) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/documents\/product-information\/blenrep-epar-product-information_en.pdf. Accessed August 4, 2021."},{"key":"10.1016\/j.clml.2022.01.011_bib0106","unstructured":"Lonial S., Lee H.C., Badros A., DREAMM-2: Single-agent belantamab mafodotin (Belamaf) in patients with relapsed\/refractory multiple myeloma (RRMM) \u20131-year outcomes by prior therapies. Poster presentation at: the American Society of Hematology (ASH) Annual Meeting and Exposition; December 5\u20138, 2020. Poster 1417."},{"key":"10.1016\/j.clml.2022.01.011_bib0107","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.clml.2022.01.011_bib0108","doi-asserted-by":"crossref","unstructured":"Nooka A.K., Stockerl-Goldstein K., Quach H., DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib\/dexamethasone in relapsed\/refractory multiple myeloma (RRMM). Oral presentation at: the American Society of Clinical Oncology Annual Meeting; May 29\u201331, 2020. Abstract 8502.","DOI":"10.1200\/JCO.2020.38.15_suppl.8502"},{"key":"10.1016\/j.clml.2022.01.011_bib0109","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the international myeloma working group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.011_bib0110","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1002\/cncr.32178","article-title":"Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.01.011_bib0111","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/bjh.15716","article-title":"Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and\/or pomalidomide refractory multiple myeloma","volume":"186","author":"Hussain","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.011_bib0112","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2017-10-809293","article-title":"The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents","volume":"131","author":"Gavriatopoulou","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0113","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-140526","article-title":"Descriptive analysis of isatuximab use following prior daratumumab in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Becnel","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0114","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2019-129021","article-title":"Elotuzumab in combination with an immunomodulatory agent (IMID) in patients with multiple myeloma refractory to IMIDs and\/or daratumumab: a single-institution analysis","volume":"134","author":"Grajales-Cruz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.011_bib0115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.01.011_bib0116","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-140697","article-title":"Efficacy and safety of the panobinostat-bortezomib-dexamethasone combination in relapsed or relapsed\/refractory multiple myeloma: results from the randomized PANORAMA 3 study","volume":"136","author":"Laubach","year":"2020","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T16:10:29Z","timestamp":1664640629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022000155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":116,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2152265022000155"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.01.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}